FIELD: medicine.
SUBSTANCE: invention relates to use of a pharmaceutical composition containing at least one compound FGF-21 (fibroblast growth factor 21) and at least one agonist GLP-1R (glucagon-like peptide-1 receptor) combined in one formulation to prepare a drug for treating type 2 diabetes in a patient.
EFFECT: invention provides a synergetic effect on oral glucose tolerance and plasma glucose levels.
10 cl, 2 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2593960C2 |
| CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY | 2010 |
|
RU2573896C2 |
| ANTIBODY SPECIFICALLY BINDING TO GLP-1R AND FUSION PROTEIN THEREOF WITH GLP-1 | 2014 |
|
RU2681857C2 |
| COMPOSITIONS, APPLICATIONS AND METHODS OF TREATING METABOLIC DISORDERS AND DISEASES | 2012 |
|
RU2697762C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| CANCER MODELS AND CORRESPONDING METHODS | 2014 |
|
RU2707531C2 |
| GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY | 2013 |
|
RU2671088C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| OXYINTOMODULINE | 2009 |
|
RU2542362C2 |
